Thursday, October 15, 2026

Riot Blockchain Stock Bullish Momentum With A 27% Jump In The Last 30 Days

Shares of Riot Blockchain rose by a staggering 27.24% in 30 days from $85.4 to $58.16 at 15:30 EST on Tuesday, after three sequential sessions in a row of gains. NASDAQ Composite is rising 1.03% to $13,992.34, following last session's downward trend, This seems, up until now, an all-around positive trend trading session today.

Riot Blockchain's last close was $51.53, 36.69% below its 52-week high of $79.50.

Riot Blockchain's Sales

Riot Blockchain's sales growth is 918.4% for the current quarter and 2421.1% for the next. The company's growth estimates for the current quarter and the next is 233.3% and 258.1%, respectively.

Riot Blockchain's Revenue

Year-on-year quarterly revenue growth grew by 340.9%, now sitting on 12.08M for the twelve trailing months.

Riot Blockchain's Stock Yearly Top and Bottom Value

Riot Blockchain's stock is valued at $58.16 at 15:30 EST, way under its 52-week high of $79.50 and way higher than its 52-week low of $0.93.

Riot Blockchain's Moving Average

Riot Blockchain's worth is higher than its 50-day moving average of $54.41 and way higher than its 200-day moving average of $22.02.

More news about Riot Blockchain.

Categories

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com